# Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

> **NCT05257408** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Corcept Therapeutics** · enrollment: 381 (actual)

## Conditions studied

- Ovarian Neoplasm
- Fallopian Tube Neoplasms
- Peritoneal Neoplasms

## Interventions

- **DRUG:** Nab-paclitaxel 80 mg/m^2
- **DRUG:** Relacorilant 150 mg once daily (QD)
- **DRUG:** Nab-paclitaxel 100 mg/m^2

## Key facts

- **NCT ID:** NCT05257408
- **Lead sponsor:** Corcept Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-06-29
- **Primary completion:** 2025-03-24
- **Final completion:** 2026-03
- **Target enrollment:** 381 (ACTUAL)
- **Last updated:** 2025-04-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05257408

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05257408, "Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05257408. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*